Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Medifast (MED) Enterprise Value (2016 - 2026)

Medifast's Enterprise Value history spans 16 years, with the latest figure at -$167.3 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 3.04% year-over-year to -$167.3 million; the TTM value through Dec 2025 reached -$167.3 million, down 3.04%, while the annual FY2025 figure was -$167.3 million, 3.04% down from the prior year.
  • Enterprise Value reached -$167.3 million in Q4 2025 per MED's latest filing, up from -$173.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$61.1 million in Q2 2022 to a low of -$212.9 million in Q1 2021.
  • Average Enterprise Value over 5 years is -$146.0 million, with a median of -$158.8 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: skyrocketed 69.07% in 2022, then plummeted 141.37% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$109.5 million in 2021, then grew by 19.95% to -$87.7 million in 2022, then crashed by 71.1% to -$150.0 million in 2023, then fell by 8.2% to -$162.3 million in 2024, then fell by 3.04% to -$167.3 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Enterprise Value are -$167.3 million (Q4 2025), -$173.5 million (Q3 2025), and -$162.7 million (Q2 2025).